Trial Search Results
Topical QR-313 in Dominant Dystrophic Epidermolysis Bullosa (DDEB) or Recessive Dystrophic Epidermolysis Bullosa (RDEB) Due to Mutation(s) in Exon 73 of the COL7A1gene
A double-blind, randomized, intra-subject placebo-controlled, multicenter, multiple dose study, evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in subjects with confirmed DDEB or RDEB diagnosis with one or more pathogenic mutations in exon 73 in the COL7A1 gene.
Stanford is currently accepting patients for this trial.
Wings Therapeutics Inc.
- Drug: QR-313
- Drug: Placebo
Phase 1/Phase 2
1. Male or female, ≥ 4 years of age at Screening with a clinical diagnosis of DDEB or
RDEB and at least one pathogenic mutation in exon 73 of the COL7A1 gene.
2. Have at least one TWA, ie, a skin area of 7 x 7 cm that ishows no signs of local
infection, and contains a target wound that is either new or shows dynamic wound
healing and complies to the following additional criteria:
1. surface area of the target wound ranging from 5 to 30 cm2, located centrally in
the selected 7 x 7 cm TWA.
2. exposed sub-epidermal tissue to allow absorption of the IMP.
3. no suspicion of current squamous cell carcinoma (SCC) upon visual inspection.
1. Pregnant or breast-feeding female
2. Hemoglobin level at Screening requiring transfusion. The subject may be rescreened
when the condition is considered stable.
3. Use of aminoglycosides, by any route of administration, except eye drops, 7 days or 5
half-lives, whichever is longer, prior to Baseline visit.
4. Untreated carcinoma of the TWA or history of carcinoma within 5 years prior to
Screening, except adequately treated cutaneous squamous or basal cell carcinoma.
5. Life expectancy less than 6 months, as assessed by the Investigator
6. Current or known history of clinically significant hepatic or renal disease, that in
the opinion of the Investigator, could impact subject safety or study participation.
7. Treatment with any systemic immunomodulators, immunosuppressants or cytotoxic
chemotherapy within 2 months prior to the Baseline visit.
8. Use of any investigational drug or device within 28 days or 5 half-lives of the
Baseline visit, whichever is longer, or plans to participate in another study of a
drug or device during the study period. The washout of 5 half-lives does not apply to
gene and cell therapy.
9. Known hypersensitivity to oligonucleotide treatment or excipients of the IMP.
10. Bleeding disorder or condition requiring the use of anticoagulants to be confirmed by
aPTT by local lab within 48 hours of first treatment.
11. Use of systemic or topical steroids within 1 month prior to the baseline visit
(inhaled and ophthalmic drops of corticosteroids or low dose topical solution of
budesonide for esophagial strictures may be allowed).
Ages Eligible for Study
4 Years - N/A
Genders Eligible for Study